Overview

Interaction Between HIV and Lymphatic Filariasis

Status:
Completed
Trial end date:
2002-11-01
Target enrollment:
0
Participant gender:
All
Summary
The impact of lymphatic filariasis (LF) on HIV is assessed by measuring HIV viral load before and after DEC treatment of filariasis in double-infected individuals. The impact of HIV on lymphatic filariasis is assessed by measuring the success of DEC treatment on W. bancrofti antigenaemia and microfilaraemia in double-infected individuals. The effect of DEC treatment in individuals with lymphatic filariasis and/or HIV is assessed by measuring the pre- and post-treatment level of HIV viral load, immunological responses and micronutritional parameters, including antioxidants and markers of oxidative stress, in single- or double-infected individuals. The study is carried out as an anonymous, unlinked and double-blind placebo controlled study with cross-over design. The study groups comprise: 1) 18 double-infected individuals (HIV+/LF+), 2) 16 HIV infected individuals (HIV+/LF-) and 3) 25 individuals with lymphatic filariasis (HIV-/LF+). Based on stratified, blocked randomisation the study participants receive DEC treatment or placebo. Pre- and post-treatment (1 week, 12 weeks and 24 weeks post-treatment) blood samples are collected and analysed for HIV viral load, CD4+ T cell count, distinctive Th1 and Th2 cytokines, circulating filarial antigens (CFA), micronutrient status, antioxidant enzymes and markers of oxidative stress. After 12 weeks the study participants get the opposite treatment and post-treatment blood samples are collected four times with the same intervals as above.
Phase:
N/A
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
DBL -Institute for Health Research and Development
Collaborators:
Danish Council for Development Research
The AIDS Foundation, Denmark
The Wedell-Wedellsborg Foundation, Denmark
Treatments:
Diethylcarbamazine
Criteria
Inclusion Criteria:

One of the three following conditions:

1. Positivity for antibodies to HIV-1 or HIV-2

2. Positivity for circulating filarial antigen from W. bancrofti

3. Positivity for both HIV antibodies and W.bancrofti circulating antigens

Exclusion Criteria:

1. AIDS

2. Hydrocele

3. Lymphoedema

4. Elephantiasis